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WS3.5 Inhaled 7% hypertonic saline treatment in preschool children
with cystic ﬁbrosis
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Objectives: Inhaled hypertonic saline (HS) improves lung function and decreases
pulmonary exacerbations in older children with cystic ﬁbrosis (CF). Early initiation
of treatment may reduce lung function decline and improve outcome. The primary
outcome was to determine if HS has a beneﬁcial effect on lung function. Secondary
outcome measures included respiratory symptoms, anthropometric measurements,
new isolation of Pseudomonas aeruginosa, rate of exacerbations, adverse events
and adherence.
Methods: In this two-center, parallel-group, open label study, 27 patients with
diagnosis of CF aged 3 to 6 years were randomly assigned to receive 7% hypertonic
saline (active group) or 0.9% isotonic saline (control group), nebulized twice daily
for 24 weeks. Salbutamol was given prior to each study drug dose.
Results: Twenty-one patients completed the study. Lung function (reﬂected by
FEV1, and impulse oscillometry parameters Rrs at 5 and 10 Hz) did not differ
signiﬁcantly between groups throughout the study. However, the absolute difference
in FEV1 at the end of the study compared to baseline FEV1 was higher in the active
group [2.4% (95%CI, −8.6 to 13.5) vs −9.25% (95%CI, −15.7 to −2.7)].
There was a subjective improvement in the effectiveness of chest physiotherapy
from baseline in the active group (p = 0.05). There was no signiﬁcant difference
in other secondary end points. Treatment with HS was well tolerated. The adverse
event proﬁle was similar in each group. Adherence was at least 80%, with no
difference between groups (p = 0.21).
Conclusion: Treatment with HS results in a slight but not signiﬁcant improvement
in pulmonary function compared with isotonic saline.
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Objectives: Lung damage in cystic ﬁbrosis develops at early stage of the disease
with an unevenness of ventilation, which affects the gas mixing efﬁciency of the
lung. The most widely used parameter of ventilation inhomogeneity is the lung
clearance index (LCI). LCI can be used as outcome measure in patients with mild
lung disease. The effect of dornase alfa and hypertonic saline on VI has been
already evaluated, showing LCI improvement. Our hypothesis was that inhaled dry
powder mannitol can inﬂuence LCI at early stage of disease.
Methods: Pilot prospective, observational study. 12 adult CF patients with normal
or near normal lung function (FEV1 >70% pred.) underwent lung function testing
and measurement of LCI using the N2MBW method (EasyOne Pro Lab), before and
after the period of 4 weeks treatment with IDPM. The primary outcome was change
in LCI. Secondary outcomes included: FEV1, FEF75−25 and patient satisfaction
with the novel medication. Concomitant use of hypertonic saline or dornase alfa
was allowed.
Results: 11 patients (4 female) 25.2 years (17−40) completed the study. After
4 weeks of mannitol treatment LCI decreased from 9.36±2.31 to 8.89±2.19, on
average by 4.6% (p = 0.044). FEV1 and FEF25−75 % changed non-signiﬁcantly.
Overall satisfaction with IDPM was high by mean seven points, range (6 to 10)
using a 10 points scale.
Conclusion: This pilot study suggests that IDPM improved ventilation inhomo-
geneity (expressed as LCI) in the CF patients with well preserved lung function
(FEV1 >70% pred.) and supports a need for larger cross-over trial in adults and
children.
